Navigation Links
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Date:7/2/2009

nnovations in patients with atrial fibrillation in the last twenty years.

The efficacy and safety of Multaq(R) 400 mg twice daily was evaluated in five controlled studies, ATHENA, ANDROMEDA, EURIDIS, ADONIS, and DAFNE, involving nearly 6,300 patients including more than 3200 patients who received Multaq(R).

The ATHENA trial, which involved 4,628 patients with AF or AFL and more than 2,300 patients receiving Multaq(R) on top of standard therapy, demonstrated a 24% reduction in time to first CV hospitalization or all-cause mortality (P<0.001) compared with placebo meeting the primary endpoint.

The ANDROMEDA study, was terminated prematurely after enrolment of 627 of 1000 planned patients with congestive heart failure, in relation to excess mortality due to worsening heart failure in the dronedarone group [n=25 versus 12 (placebo), p=0.027].

The patient population enrolled in the ANDROMEDA and ATHENA studies was significantly different. The patients enrolled in ANDROMEDA had relatively severe heart failure and had been hospitalized, or referred to a specialty heart failure clinic for worsening symptoms. Patients were predominantly NYHA II and III (New York Heart Association classification) and only 25% had a history of AF/AFL at randomization. In contrast, in ATHENA, all patients had a history of AF/AFL, and 71% of patients had no heart failure, 25% were NYHA class I or II, and only 4% were class III.

The ANDROMEDA and ATHENA trials were published in the New England Journal of Medicine (NEJM) respectively in 2008 and 2009.

Important Safety Information

Multaq(R) is contraindicated in patients with NYHA Class IV heart failure or NYHA Class II-III heart failure with a recent decompensation requiring hospitalization or referral to a specialized heart failure clinic. In a placebo-controlled study in patients with severe heart failure requiring recent
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
2. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
3. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
4. ClearWay Minnesota(SM) Board Approves Four Regional Grants
5. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
6. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
7. Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
8. FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
9. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
10. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
11. FDA Approves Plan B Pill for 17-Year-Olds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... (PRWEB) September 02, 2014 Lseat.com is one ... covers . All its products are user-friendly items; no professional ... original seat covers; they can slip right over the cars’ ... Now, the company’s website is filled with various kinds of ... its new designs of Jeep leather seat covers . ...
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 A ... for everyone. But sometimes the onset of irritability, sadness, ... condition, reports the September 2014 Harvard Health Letter. ... response to everyday stresses. If they occur for long ... it's an indication to seek help," says Dr. Nancy ...
(Date:9/2/2014)... September 02, 2014 Researchers in New Delhi, ... developed mesothelioma after being exposed to asbestos-contaminated work clothes for ... the details of the report in a new article. ... the ESI Model Hospital say their patient was diagnosed ... Further investigation found that she had come in contact with ...
(Date:9/2/2014)... 2014 Eric Jimenez and Leah Ashley ... a revolutionary makeup application device. Designed to improve and ... in the palm of women’s hands to help them ... Color Me’s success lies in its patented technology. With ... of 15,000 pulses per minute, the device applies foundation ...
(Date:9/2/2014)... 2014 Innovations Television, produced by ... content for upcoming episodes of Innovations, focusing on ... 2015. , Innovations, hosted by Ed Begley, Jr., ... breakthroughs and advancements taking place in all areas ... advancements in biosciences. Biosciences are at the core ...
Breaking Medicine News(10 mins):Health News:High Quality 1997-2006 JEEP Wrangler TJ Leather Seat Covers From Popular Supplier Lseat.com 2Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2Health News:New Report Illustrates That Even Brief Asbestos Exposure Can Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Exciting New Episodes of Innovations with Ed Begley Jr to Air via Discovery Channel 2
... Ill., May 13 Z Trim Holdings, Inc.,(Amex: ... statements,for the fiscal year ended December 31, 2007 contained ... accounting,firm, Blackman Kallick LLP. This announcement is being made ... which requires separate disclosure,of receipt of an audit opinion ...
... today signed three bills into law:, Senate Bill ... pharmacies, under the supervision of the State Board of,Pharmacy, ... Under the program, drugs may be returned to an ... their original packaging and the,drug expires no sooner than ...
... Company Management to discuss the benefits of Hemodiafiltration therapy and ... of Life for End-Stage Renal Disease Patients, NEW YORK, ... device company developing and marketing products designed to,improve the quality ... the critical financial and clinical needs of the care,provider, today ...
... May 13 eDiets.com,Inc. (Nasdaq: DIET ), leveraging ... healthy lifestyle solutions to everyone, today announced,results for the ... first quarter of 2008 were $8.8 million, compared to,$8.4 ... for the quarter,was $(5.1) million, or $(0.20) per diluted ...
... heres another reason to encourage your daughters to be physically ... ages of 12 and 35 have a substantially lower risk ... less active, new research shows. , In the largest ... exercise on premenopausal breast cancer, the study of nearly 65,000 ...
... underwent circulatory procedure , , TUESDAY, May 13 (HealthDay ... that the clot-preventing drug Plavix could help in the ... suitable for dialysis for kidney patients. , Giving Plavix ... would block the vessel created by combining a vein ...
Cached Medicine News:Health News:Z Trim Holdings, Inc. Audit Report Contains 'Going Concern' Qualification 2Health News:Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008 2Health News:Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008 3Health News:Nephros Exhibits at the XLV ERA-EDTA Congress in Stockholm, Sweden, May 10-13, 2008 4Health News:eDiets.com(R) Announces Q1 2008 Results 2Health News:eDiets.com(R) Announces Q1 2008 Results 3Health News:eDiets.com(R) Announces Q1 2008 Results 4Health News:eDiets.com(R) Announces Q1 2008 Results 5Health News:eDiets.com(R) Announces Q1 2008 Results 6Health News:Girls, young women can cut risk of early breast cancer through regular exercise 2Health News:Blood-Thinner No Help for Dialysis Treatment 2
(Date:9/2/2014)... , September 2, 2014 ... Genetics has become the first European company to obtain ... Generation Sequencing (NGS) bioinformatic pipeline for routine genetic testing. ... in raising the standards of routine genetic testing ... Data Driven Medicine platform to a wider market. ...
(Date:9/2/2014)... Biotech Ltd. (NASDAQ: SVA ), a leading provider ... announced that the Company,s management will participate in the following ... Healthcare Conference, to be held at the Grand Hyatt New ... Stanley Asia Pacific Healthcare Day, to be held at the ... Healthcare & Technology Conference, to be held at the Wynn ...
(Date:9/2/2014)... , Sept. 2, 2014 Legal-Bay LLC, ... increase in capital and cash advance funding for ... System,s da Vinci Robot. With over 400k surgeries ... focuses on providing lawsuit cash advances for victims ... damage, lacerations to internal organs, burns to blood ...
Breaking Medicine Technology:Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2Sinovac to Participate in Upcoming Investor Conferences 2da Vinci Lawsuit Settlement Funding Amounts Increased at Legal-Bay Funding 2da Vinci Lawsuit Settlement Funding Amounts Increased at Legal-Bay Funding 3
... 7, 2011 Reportlinker.com announces that a new ... The 2011 Top Ten ... http://www.reportlinker.com/p0368704/The-2011-Top-Ten-World,s-Leading-Pharmaceutical-Companies.html A thought-provoking report ... major competitors in the worldwide pharmaceutical market. The ...
... 7, 2011 Reportlinker.com announces that a ... its catalogue: Aesthetic Devices ... be Driven by Improving Treatment Outcomes and ... http://www.reportlinker.com/p0409144/Aesthetic-Devices-Market-to-2017---Future-Growth-to-be-Driven-by-Improving-Treatment-Outcomes-and-Increase-in-Consumer-Confidence.html Aesthetic ...
Cached Medicine Technology:Reportlinker Adds The 2011 Top Ten World's Leading Pharmaceutical Companies 2Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 2Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: